Finch Therapeutics Group (NASDAQ:FNCH) Issues Earnings Results

Finch Therapeutics Group (NASDAQ:FNCH) released its quarterly earnings data on Monday. The company reported ($1.89) earnings per share (EPS) for the quarter, reports.

Finch Therapeutics Group Trading Up 7.4 %

Shares of Finch Therapeutics Group stock opened at $2.84 on Thursday. The stock has a 50 day moving average price of $2.66 and a 200-day moving average price of $3.61. Finch Therapeutics Group has a one year low of $2.19 and a one year high of $16.74.

Hedge Funds Weigh In On Finch Therapeutics Group

A number of institutional investors and hedge funds have recently modified their holdings of FNCH. BlackRock Inc. boosted its holdings in Finch Therapeutics Group by 2.3% during the 1st quarter. BlackRock Inc. now owns 404,931 shares of the company’s stock valued at $2,038,000 after acquiring an additional 9,149 shares during the period. Renaissance Technologies LLC raised its position in shares of Finch Therapeutics Group by 202.7% in the 4th quarter. Renaissance Technologies LLC now owns 122,900 shares of the company’s stock worth $59,000 after acquiring an additional 82,300 shares in the last quarter. Millennium Management LLC bought a new position in shares of Finch Therapeutics Group in the 2nd quarter worth $259,000. Vanguard Group Inc. increased its position in Finch Therapeutics Group by 10.0% during the 3rd quarter. Vanguard Group Inc. now owns 35,939 shares of the company’s stock valued at $186,000 after buying an additional 3,263 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new position in Finch Therapeutics Group during the 2nd quarter valued at about $98,000. Hedge funds and other institutional investors own 21.77% of the company’s stock.

About Finch Therapeutics Group

Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease.